Boehringer Ingelheim enters collaboration on hearing loss treatment for up to USD 100m
Biotech firm Autigen has inked a research collaboration and license agreement with Boehringer Ingelheim to discover and develop treatments for hearing loss.
by albert rønning-andersson, translated by daniel pedersen
German Boehringer Ingelheim and US-based biotech firm Autigen are partnering up to discover and develop potential hearing loss treatments, the company has announced in a press release on Wednesday, as reported by industry media Fierce Biotech.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
